FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Investigator-led clinical trial of boron neutron capture therapy system for recurrent high-grade meningiomas after radiation therapy: Randomized phase II study. PMID 41560342 · Neuro Oncol · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Correction to: Randomized, Double-Blind, Active-Controlled Phase 3 Study to Evaluate Efficacy and Safety of Zastaprazan Compared to Esomeprazole in Erosive Esophagitis. PMID 41556513 · Am J Gastroenterol · 2026-Apr-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Vitamin D for tuberculosis or acute respiratory infections: lost in translation? PMID 41549871 · Curr Opin Infect Dis · 2026-Apr-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial. PMID 41537701 · Clin Cancer Res · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials. PMID 41500250 · J Natl Cancer Inst · 2026-Apr-01 This is an individual patient data meta-analysis of multiple RCTs, not a primary report of a single trial with a drug intervention. While it analyzes phase III trials, it is a secondary analysis, and the original trials are not individually reported here with their drug-specific results. The study focuses on statistical methodology (conditional survival) rather than reporting the efficacy of a specific drug intervention. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy. PMID 41428405 · Clin J Am Soc Nephrol · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD). PMID 41422917 · Int J Radiat Oncol Biol Phys · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Prospective, randomized dose-escalation trial with proton-based radiation for skull base and cervical spine chondrosarcomas: 30-year outcomes from PROG 85-26. PMID 41414803 · Neuro Oncol · 2026-Apr-01 The study is a randomized trial reporting time-to-event efficacy results, but it lacks an explicit drug-containing intervention and does not clearly establish a definitive Phase III/IIIb or Phase II/III status. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Phase III Randomized Controlled Trial of Pyloroplasty Versus No Pyloroplasty in Patients Undergoing Minimally Invasive Esophagectomy or Robot-assisted Minimally Invasive Esophagectomy. PMID 41413794 · Ann Surg · 2026-Apr-01 干预为非药物单独策略,未满足药物干预要求。 |
H
L
B
|
旧查询独有 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With Guselkumab. PMID 41326161 · J Rheumatol · 2026-Apr-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial. PMID 41275977 · Int J Radiat Oncol Biol Phys · 2026-Apr-01 The report is a Phase III randomized trial in human oncology, but the intervention is non-drug-only (stereotactic vs. hypofractionated radiation therapy) and the primary endpoint is quality-of-life, not a time-to-event efficacy outcome (e.g., OS, PFS). Therefore, it does not meet the eligibility criteria for a drug-containing intervention with a primary/key secondary time-to-event endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Artificial Intelligence Analysis of Endoscopy Outperforms Conventional Endoscopic Scoring for Agreement With Symptoms and Quality of Life in a Phase 3 Ulcerative Colitis Trial. PMID 41247057 · Am J Gastroenterol · 2026-Apr-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Controlled trial of cervical cancer screening frequency among human-papillomavirus-vaccinated women. PMID 41203578 · Int J Cancer · 2026-Apr-01 The record describes a randomized trial in cervical cancer screening frequency among HPV-vaccinated women. It meets criteria for oncology, human, randomized, time-to-event, and original result. However, the intervention is a screening frequency (low- vs. high-intensity cytology), not a drug-containing therapeutic intervention. The trial phase is not explicitly stated as Phase III/IIIb or II/III; the metadata lacks definitive phase information. Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Exclusion of patients with renal impairment from phase 3 randomized controlled trials in hematologic malignancies. PMID 41195829 · Int J Cancer · 2026-Apr-01 The record describes a meta-analytic study examining the exclusion of patients with renal impairment from phase 3 RCTs in hematologic malignancies. While it is oncology, human, randomized, phase 3, and involves drug interventions, it is not an original result report of a single trial. It lacks a primary time-to-event efficacy endpoint, as its outcomes are about trial design (eligibility criteria), not patient outcomes like OS or PFS. Therefore, it is excluded. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Postoperative Single-Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer With GammaPod Technology: A Phase 2 Clinical Trial. PMID 41161644 · Int J Radiat Oncol Biol Phys · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Electro-acupuncture for quality of life during adjuvant chemotherapy in gastric cancer: a randomized trial. PMID 41143548 · J Natl Cancer Inst · 2026-Apr-01 The study is excluded because the primary intervention under evaluation is electro-acupuncture (a non-drug modality), not a drug-containing intervention, which is a required criterion. Additionally, the trial phase is not definitively established as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Five-Year Survival and Safety of SABR in Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer unfit for Concurrent Radio-chemotherapy: Focus on Patterns of Local Recurrence from the START-NEW-ERA Non-randomized Phase 2 Trial. PMID 40992670 · Int J Radiat Oncol Biol Phys · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The National Health Service-Galleri multicancer screening trial: explanation and justification of unique and important design issues. PMID 40795803 · J Natl Cancer Inst · 2026-Apr-01 The record is an explanatory article about the NHS-Galleri screening trial's design and justification. While it is an oncology RCT in humans with a definitive (Phase III) screening design, it does not meet two core eligibility criteria: (1) it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR), as its primary outcome is late-stage cancer incidence, which is a diagnostic/screening endpoint; and (2) the intervention is a diagnostic test, not a drug-containing intervention. Furthermore, it is not an original result report but a design rationale paper. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled Trial. PMID 40772617 · Ann Surg · 2026-Apr-01 The study is an oncology randomized trial with a primary OS endpoint, but it compares two surgical techniques for pancreatic cancer, not drug-containing interventions. Therefore, it does not meet the drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Assessing the Impact of Media Coverage of the NordICC Trial on Public Perspectives on Colonoscopy for Colorectal Cancer Screening. PMID 39907707 · J Clin Gastroenterol · 2026-Apr-01 The record describes a survey study assessing public perception of media coverage about a cancer screening trial (NordICC). While it is a randomized study in an oncology context, it does not meet key eligibility criteria: it is not a clinical trial of a drug intervention (the 'intervention' is a media article), it is not a Phase III/IIIb or Phase II/III trial, and it has no time-to-event efficacy endpoint. The primary outcome is a change in intent to undergo colonoscopy, which is a behavioral/attitudinal measure, not a clinical survival or progression endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Positive Resection Margins on Recurrence and Survival After Resection and Adjuvant Chemotherapy in Pancreatic Cancer: Results of the PRODIGE 24-CCTG PA-6 Randomized Controlled Trial. PMID 39041211 · Ann Surg · 2026-Apr-01 The record describes a secondary analysis (prognostic impact of resection margins) of a phase III randomized trial (PRODIGE 24/CCTG PA-6). While the parent trial is eligible, this specific report is a secondary analysis focusing on prognostic factors, not the primary efficacy comparison of the randomized intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of a Multidimensional Digital Health Intervention on Quality of Life in Breast Cancer Survivors: A Randomized Controlled Trial. PMID 42361286 · JCO Clin Cancer Inform · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Design and implementation of interventions to improve sexual health of women with endometriosis: A mixed-methods study protocol with an interventional design. PMID 42312110 · Int J Reprod Biomed · 2026-Apr 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease. PMID 42287159 · Curr Med Res Opin · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the Asian subgroup of the RATIONALE-305 study. PMID 42262249 · Curr Med Res Opin · 2026-Apr The report is from a Phase III randomized trial but the primary analysis is of patient-reported outcomes (quality of life), not a formal efficacy endpoint like overall survival or progression-free survival. The deterministic review correctly identified the absence of a time-to-event efficacy signal. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Magnetic resonance imaging-guided radiotherapy for prostate cancer: A systematic review of the literature. PMID 42229011 · Cancer Radiother · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. PMID 42181314 · Cureus · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Integrating adjuvant therapy as standard multimodal treatment for patients with esophageal cancer after neoadjuvant therapy. PMID 42089821 · Minerva Surg · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Serum Biomarkers and CT-Derived Muscle Indices in Sarcopenia Associated with Pancreatic Neoplasm: A Comparative Clinical Study. PMID 42084250 · Chirurgia (Bucur) · 2026-Apr The study is a randomized prospective biomarker and imaging study comparing patients with pancreatic neoplasm and sarcopenia to controls. While it involves human oncology patients and has a randomized design, it does not contain a drug-containing intervention (it is an observational/diagnostic biomarker study) and does not report a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, etc. The study's focus is on diagnostic/prognostic biomarkers and sarcopenia assessment, not the efficacy of a therapeutic drug. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Treating maternal mental health problems with an app-based program: A randomized control trial of the Building Emotional Awareness and Mental Health (BEAM) program, for mothers of young children. PMID 42080862 · J Consult Clin Psychol · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Strengthening self-continuity to reduce depressive symptoms and derailment: A multiphasic mixed-methods randomized controlled trial. PMID 42080860 · J Consult Clin Psychol · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Induction chemotherapy plus bevacizumab or radiotherapy in N2 non-squamous non-small cell lung cancer: 5-year results of a randomized phase 2 trial. PMID 42079970 · JTCVS Open · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Development and Validation of Flow Cytometry-Based Method to Quantify CD34/CD45+ Cells as a Release Criterion of Clinical-Grade Products for a Phase III Clinical Trial. PMID 42071167 · Cytometry A · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of gepotidacin versus standard of-care antibiotics for the treatment of uncomplicated urogenital infections in adults and adolescents: a systematic review and meta-analysis. PMID 42047482 · Expert Rev Anti Infect Ther · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of Once-Daily Macitentan 75 mg on the Pharmacokinetics of Sildenafil, Riociguat, or Rosuvastatin in Healthy Male Participants. PMID 42023995 · J Clin Pharmacol · 2026-Apr The record describes a Phase I pharmacokinetic study in healthy volunteers for pulmonary arterial hypertension, not an oncology trial. It lacks a time-to-event efficacy endpoint and is not a definitive randomized trial in cancer patients. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Impact of Endoscopic Ultrasound and Multidisciplinary Team Evaluation on the Management of Pancreatic Cystic Lesions. PMID 42023483 · United European Gastroenterol J · 2026-Apr The record is a randomized, crossover study evaluating diagnostic accuracy and cognitive bias in multidisciplinary team review of pancreatic cystic lesions, not a drug intervention trial for cancer treatment with time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis. PMID 42022227 · BJUI Compass · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Web-Based Cognitive Rehabilitation for Patients With Aggressive Lymphoma With Perceived Cognitive Impairment: A Randomised Pilot Study. PMID 42012802 · Psychooncology · 2026-Apr The study is an oncology randomized trial with original results, but it is excluded because it is a pilot study (not Phase III/IIIb or definitive Phase II/III), involves a non-drug intervention (cognitive rehabilitation), and does not have a time-to-event efficacy endpoint (primary outcomes are feasibility, neuropsychological tests, and patient-reported outcomes). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A novel methodology using direct patient contact and UK national registries to collect long-term data from randomised trials: TARGIT-X - an extended follow-up study of the TARGIT-A trial of targeted intraoperative radiotherapy for breast cancer. PMID 42011087 · Health Technol Assess · 2026-Apr The report is a methodology and feasibility study for collecting long-term follow-up data from an existing randomized trial (TARGIT-A). It does not report the primary efficacy results (e.g., OS, local control) of the original trial with a drug intervention. The intervention is radiotherapy (a procedure), not a drug. Therefore, it fails the required criteria for drug intervention and time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Rezvilutamide plus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer patients after progression on abiraterone: A multi-centre, open-label, phase II trial. PMID 41987598 · Clin Transl Med · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial. PMID 41986500 · Nat Cancer · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Keynote-177 Randomized Controlled Trial of First-line PD-1 Blockade for Microsatellite-High or Mismatch Repair-Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross-Over Trial Design and Related Issues. PMID 41980913 · Cancer Med · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trial. PMID 41962307 · ESMO Open · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial. PMID 41962306 · ESMO Open · 2026-Apr The record describes a secondary analysis of patient-reported outcomes and qualitative interviews from a Phase III randomized drug trial. It does not report the primary or key secondary time-to-event efficacy results (e.g., OS, PFS) of the trial itself, which are required for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Difelikefalin in Chinese patients with chronic kidney disease-associated pruritus. PMID 41948117 · Clin Kidney J · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Missingness in Eligibility Criteria for Target Trial Emulation in EHR With Survival Outcomes. PMID 41944336 · Stat Med · 2026-Apr This is a methodological study about handling missing data in target trial emulation using EHR, not a report of an original randomized clinical trial. While it mentions an oncology context and survival outcomes, it is not a clinical trial report with drug intervention results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Emerging treatments in hypertrophic cardiomyopathy: a focus on cardiac myosin inhibitors. PMID 41940719 · Expert Opin Pharmacother · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Exploring Early Antifungal Activity of Rezafungin as a Stepping-Stone for Shorter Treatment Duration for Candidemia: Pooled Analysis of 2 Randomized Trials. PMID 41940006 · Open Forum Infect Dis · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Carboplatin-capecitabine in concurrent chemoradiation for LA-HNSCC: could it be a safer alternative to high-dose cisplatin? PMID 41939105 · Ann Med Surg (Lond) · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Lenalidomide Plus Dexamethasone as FIRST-Line Therapy in Transplant-Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non-Interventional Study FIRST-NIS and Comparison With the FIRST Pivotal Phase III Clinical Trial. PMID 41927857 · Cancer Med · 2026-Apr The study is a prospective, non-interventional (observational) study comparing real-world outcomes to a previous pivotal trial. While it reports Phase III and time-to-event endpoints with a drug intervention, it lacks the core requirement of being a randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |